Unit of Cancer Survivorship, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), PO Box 101949, 69009, Heidelberg, Germany.
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
J Cancer Res Clin Oncol. 2022 Dec;148(12):3461-3473. doi: 10.1007/s00432-022-04204-w. Epub 2022 Jul 25.
It is important to monitor disease-specific health-related quality of life (HRQoL) in breast cancer (BC) survivors to identify potential unmet supportive care needs. However, previous studies were characterized by small samples of mostly short-term survivors and were limited to certain age ranges, stages and/or treatments.
We used data from 3045 long-term BC survivors (5-15 years post-diagnosis) recruited in a German multi-regional population-based study. We assessed disease-specific HRQoL with the EORTC QLQ-BR23, scoring from 0 to 100. Differences in functioning and symptoms according to age at survey, self-reported treatments, stage, and disease status (disease-free vs. active disease) were assessed with multiple regression. Active disease was defined as any self-report of recurrence, metastasis or second primary cancer after the index cancer.
Older BC survivors reported a higher body image and a better future perspective, but lower sexual functioning. Survivors aged 30-49 years who had breast-conserving therapy or mastectomy with breast reconstruction reported a better body image compared to those who had mastectomy only. We also found differences in symptoms according to treatments in some age groups. Stage at diagnosis was not associated with HRQoL overall and in most age subgroups. Disease-free BC survivors aged 30-79 years reported a better future perspective and less systemic therapy side effects than those with active disease.
Several treatment-associated symptoms and functioning detriments were found 5-15 years after diagnosis. The results emphasize the need of a comprehensive, individualized survivorship care, recognizing differential needs of long-term BC survivors according to age, treatment modalities, and disease status.
监测乳腺癌(BC)幸存者的特定疾病健康相关生活质量(HRQoL)非常重要,以识别潜在的未满足的支持性护理需求。然而,以前的研究样本量较小,主要是短期幸存者,且仅限于特定的年龄范围、阶段和/或治疗方法。
我们使用了一项德国多区域基于人群的研究中招募的 3045 名长期 BC 幸存者(诊断后 5-15 年)的数据。我们使用 EORTC QLQ-BR23 评估了特定于疾病的 HRQoL,评分范围为 0 至 100。根据调查时的年龄、自我报告的治疗方法、阶段和疾病状态(无疾病 vs. 活动性疾病),使用多元回归评估了功能和症状的差异。活动性疾病定义为指数癌症后任何自我报告的复发、转移或第二原发癌。
年龄较大的 BC 幸存者报告了更高的身体形象和更好的未来展望,但性功能较低。接受保乳治疗或乳房切除术加乳房重建的 30-49 岁年龄组的幸存者与仅接受乳房切除术的幸存者相比,身体形象更好。我们还发现,在某些年龄组中,根据治疗方法的不同,症状也存在差异。诊断时的阶段总体上与 HRQoL 无关,且在大多数年龄亚组中也无关。30-79 岁无疾病的 BC 幸存者报告的未来展望更好,且系统治疗副作用比活动性疾病的幸存者更少。
在诊断后 5-15 年内发现了几种与治疗相关的症状和功能损害。结果强调需要进行全面、个体化的生存护理,根据年龄、治疗方式和疾病状态,识别长期 BC 幸存者的不同需求。